
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. has experienced a significant growth in its POC and formulary offerings, with an increase of more than 100% during the last buying season, showcasing strong demand for its specialized digital tools tailored for medical professionals. The company's shares have shown positive momentum, rising 3.2% since September 8, which indicates growing investor confidence. Additionally, the second quarter guidance appears attainable with potential for upside, suggesting robust operational performance and increasing visibility in the market driven by expanded product offerings.
Bears say
Doximity's stock has a negative outlook due to uncertainty in the economic environment, which has prompted downward guidance revisions from its pharmaceutical clients for fiscal years 2023 and 2024. Additionally, Doximity's shares are perceived as expensive when compared to its software peers, suggesting potential volatility if the company fails to meet high investor expectations. There is heightened scrutiny regarding the company's financial performance, and any inability to deliver positive results or raise guidance could lead to significant disappointment among investors.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares